CYC 065

Drug Profile

CYC 065

Alternative Names: CYC-065

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Antineoplastics; Purines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell cycle protein inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Neuroblastoma

Most Recent Events

  • 09 Aug 2017 Cyclacel Pharmaceuticals plans a phase I/II trial of CYC 065 in Chronic lymphocytic leukaemia (Combination therapy)
  • 07 Aug 2017 Pharmacodynamics and adverse events data from a phase I trial in Cancer released by Cyclacel Pharmaceuticals
  • 02 Apr 2017 Pharmacodynamics data from preclinical trial in Lung cancer released by Cyclacel Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top